162. 類天疱瘡（後天性表皮水疱症を含む。） Pemphigoid Clinical trials / Disease details
臨床試験数 : 90 / 薬物数 : 122 - (DrugBank : 47) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 144
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04128176 (ClinicalTrials.gov) | May 25, 2023 | 12/10/2019 | Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid | An Open-Label Study to Evaluate the Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid | Bullous Pemphigoid | Drug: Rituximab combined with Omalizumab | University of California, Davis | NULL | Not yet recruiting | 18 Years | 90 Years | All | 15 | Phase 3 | United States |
| 2 | NCT05520086 (ClinicalTrials.gov) | November 11, 2022 | 22/8/2022 | Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. | Phase IIa Multicenter Clinical Trial to Determine the Feasibility and Safety of the Use of Adipose-derived Mesenchymal Stem Cells (ASC) in the Treatment of Patients With Cicatricial Conjunctivitis Associated With Lyell's Syndrome, Stevens-Johnson Syndrome and Pemphigoid of the Mucous Membranes With Ocular Involvement. | Chronic Conjunctivitis;Stevens-Johnson Syndrome;Lyell Syndrome;Pemphigoid | Drug: Single Dose;Drug: Double Dose | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Effice Servicios Para la Investigacion S.L. | Recruiting | 18 Years | N/A | All | 20 | Phase 1/Phase 2 | Spain |
| 3 | NCT05594472 (ClinicalTrials.gov) | November 1, 2022 | 21/10/2022 | Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid | Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid Compared to Conventional Topical Treatment | Pemphigus Vulgaris;Bullous Pemphigoid | Drug: Ozonated olive oil;Drug: Topical garamycin cream | Cairo University | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 3 | Egypt |
| 4 | NCT05649579 (ClinicalTrials.gov) | September 1, 2022 | 6/12/2022 | Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid | Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid: a Multicenter Retrosepctive Study | Bullous Pemphigoid | Drug: Dupilumab | Peking University First Hospital | Ruijin Hospital;Cancer Institute and Hospital, Chinese Academy of Medical Sciences;West China Hospital;Second Xiangya Hospital of Central South University;Shandong Provincial Institute of Dermatology and Venereology | Recruiting | 18 Years | N/A | All | 146 | China | |
| 5 | EUCTR2021-005486-40-ES (EUCTR) | 22/07/2022 | 11/02/2022 | Clinical Trial to evaluate safety and efficacy of cell therapy in patients with cicatricial conjuntivitis | Phase IIa multicenter clinical trial to determine the feasibility and safety of the use of adipose-derived mesenchymal stem cells (ASC) in the treatment of patients with cicatricial conjunctivitis associated with Lyell's syndrome, Stevens-Johnson syndrome and pemphigoid of the mucous membranes with ocular involvement. | Cicatricial conjunctivitis associated with Lyell's syndrome, Stevens-Johnson syndrome and mucous membrane pemphigoid with ocular involvement.;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: allogenic mesenchymal stem cell isolated from adipose tissue INN or Proposed INN: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED Other descriptive name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED Product Name: allogenic mesenchymal stem cell isolated from adipose tissue INN or Proposed INN: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED Other descriptive name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED | FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | Spain | ||
| 6 | NCT05267600 (ClinicalTrials.gov) | June 9, 2022 | 14/2/2022 | A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD) | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | Bullous Pemphigoid | Biological: efgartigimod PH20 SC;Other: placebo;Drug: Prednisone | argenx | NULL | Recruiting | 18 Years | N/A | All | 160 | Phase 2/Phase 3 | United States;Australia;Bulgaria;Croatia;France;Germany;Greece;Hungary;Israel;Italy;Latvia;Netherlands;Poland;Serbia;Spain;United Kingdom |
| 7 | EUCTR2021-003087-27-BG (EUCTR) | 19/05/2022 | 07/03/2022 | A study to assess the efficacy and safety of a subcutaneous formulation of efgartigimod PH20 in adults with bullous pemphigoid. | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid - A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Efgartigimod PH20 SC INN or Proposed INN: EFGARTIGIMOD ALFA | argenx BV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 2;Phase 3 | Serbia;United States;Czechia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Poland;Croatia;Romania;Australia;Bulgaria;Germany;Latvia;Netherlands;China;Japan | ||
| 8 | NCT05061771 (ClinicalTrials.gov) | May 6, 2022 | 15/9/2021 | Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) | A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) | Bullous Pemphigoid | Drug: nomacopan (rVA576);Other: Placebo | AKARI Therapeutics | NULL | Withdrawn | 18 Years | 99 Years | All | 0 | Phase 3 | United States;Germany;Netherlands;Poland |
| 9 | EUCTR2021-003087-27-HR (EUCTR) | 29/04/2022 | 16/05/2022 | A study to assess the efficacy and safety of a subcutaneous formulation of efgartigimod PH20 in adults with bullous pemphigoid. | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid - A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Efgartigimod PH20 SC INN or Proposed INN: EFGARTIGIMOD ALFA | argenx BV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 2;Phase 3 | Germany;China;Japan;Australia;Bulgaria;Serbia;United States;Greece;Spain;Ukraine;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Poland;Croatia | ||
| 10 | ChiCTR2200058412 | 2022-04-28 | 2022-04-09 | A clinical study to evaluate the effectiveness and safety of Dupilumab injection (Dupixent ?R) in the treatment of mild to moderate bullous pemphigoid | A clinical study to evaluate the effectiveness and safety of Dupilumab injection (Dupixent ?R) in the treatment of mild to moderate bullous pemphigoid | Bullous Pemphigoid, BP | Experimental group:Dupilumab; | Xijing Hospital | NULL | Pending | Both | Experimental group:8; | China | |||
| 11 | EUCTR2020-005987-67-NL (EUCTR) | 22/04/2022 | 24/11/2021 | A study to see if 24-weeks of treatment with nomacopan works and is safe in adult patients with bullous pemphigoid who are also being treated with steroid tablets | A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pemphigoid receiving adjunct oral corticosteroid therapy (ARREST-BP) | moderate to severe bullous pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: nomacopan Product Code: rVA576 INN or Proposed INN: NOMACOPAN Other descriptive name: rVA576 | Akari Therapeutics Plc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 3 | United States;Germany;Netherlands | ||
| 12 | EUCTR2021-003087-27-ES (EUCTR) | 13/04/2022 | 24/02/2022 | A study to assess the efficacy and safety of a subcutaneous formulation of efgartigimod PH20 in adults with bullous pemphigoid. | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid - A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Efgartigimod PH20 SC INN or Proposed INN: EFGARTIGIMOD ALFA | argenx BV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 2;Phase 3 | United States;Serbia;Greece;Spain;Ukraine;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Poland;Croatia;Australia;Bulgaria;Germany;China;Japan | ||
| 13 | EUCTR2021-003087-27-HU (EUCTR) | 29/03/2022 | 09/02/2022 | A study to assess the efficacy and safety of a subcutaneous formulation of efgartigimod PH20 in adults with bullous pemphigoid. | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid - A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Efgartigimod PH20 SC INN or Proposed INN: EFGARTIGIMOD ALFA | argenx BV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 2;Phase 3 | United States;Serbia;Greece;Spain;Ukraine;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Poland;Croatia;Australia;Bulgaria;Germany;China;Japan | ||
| 14 | NCT05263505 (ClinicalTrials.gov) | February 21, 2022 | 16/2/2022 | Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid | Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid | Mucous Membrane Pemphigoid;Cicatrizing Conjunctivitis | Drug: Baricitinib 2 MG [Olumiant];Drug: Methotrexate;Drug: Azathioprine;Drug: Mycophenolate | Washington University School of Medicine | Eli Lilly and Company | Recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |
| 15 | EUCTR2020-005987-67-DE (EUCTR) | 22/12/2021 | 16/07/2021 | A study to see if 24-weeks of treatment with nomacopan works and is safe in adult patients with bullous pemphigoid who are also being treated with steroid tablets | A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pemphigoid receiving adjunct oral corticosteroid therapy (ARREST-BP) | moderate to severe bullous pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: nomacopan Product Code: rVA576 INN or Proposed INN: NOMACOPAN Other descriptive name: rVA576 | Akari Therapeutics Plc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 3 | United States;Germany | ||
| 16 | EUCTR2020-000287-32-GR (EUCTR) | 04/11/2021 | 13/09/2021 | A study to investigate the use of benralizumab in patients with bullous pemphigoid | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD) - FJORD | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Fasenra Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab Other descriptive name: benralizumab | AstraZeneca AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 3 | France;United States;Greece;Spain;Australia;Bulgaria;Israel;Germany;United Kingdom;Italy;Japan;China | ||
| 17 | EUCTR2020-000287-32-DE (EUCTR) | 12/04/2021 | 16/10/2020 | A study to investigate the use of benralizumab in patients with bullous pemphigoid | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD) - FJORD | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Fasenra Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab Other descriptive name: benralizumab | AstraZeneca AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 3 | United States;France;Greece;Spain;Australia;Israel;Bulgaria;Germany;Japan;Italy;China | ||
| 18 | NCT04612790 (ClinicalTrials.gov) | March 31, 2021 | 12/10/2020 | A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD) | Bullous Pemphigoid | Biological: Benralizumab;Biological: Placebo | AstraZeneca | NULL | Recruiting | 18 Years | 130 Years | All | 120 | Phase 3 | United States;Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain |
| 19 | JPRN-jRCT2071210014 | 26/03/2021 | 26/04/2021 | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid. | The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP). - FJORD | Bullous Pemphigoid | This study is designed to assess the efficacy and safety of a benralizumab 60 mg loading dose followed by repeat dosing of subcutaneously (SC) administered benralizumab 30 mg versus placebo in adult participants with symptomatic BP. Following screening, about 120 eligible participants will be randomized 1:1 to receive either benralizumab or placebo. Double-blind treatment period (0w-36w): In the benralizumab group, 60 mg initially and 30 mg thereafter are subcutaneously administered every 4 weeks. In the placebo group, placebo is subcutaneously administered every 4 weeks. Open-label extension period (36w-): All participants who complete the double-blind dosing period will be given the option of receiving benralizumab 30 mg subcutaneously every 4 weeks. | Hibi Kazushige | NULL | Recruiting | >= 18age old | Not applicable | Both | 12 | Phase 3 | United States;Australia;Bulgaria;France;Germany;Israel;Italy;Spain;Japan |
| 20 | EUCTR2020-000287-32-FR (EUCTR) | 09/02/2021 | 03/11/2020 | A study to investigate the use of benralizumab in patients with bullous pemphigoid | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid - FJORD | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab Other descriptive name: benralizumab | AstraZeneca AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 3 | United States;France;Spain;Australia;Israel;Bulgaria;Germany;Japan;Italy | ||
| 21 | EUCTR2020-000287-32-IT (EUCTR) | 22/01/2021 | 24/05/2021 | A study to investigate the use of benralizumab in patients with bullous pemphigoid | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid - FJORD | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Benralizumab Product Code: [MEDI-563] INN or Proposed INN: Benralizumab | ASTRAZENECA AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 3 | France;United States;Spain;Australia;Bulgaria;Israel;Germany;Japan;Italy | ||
| 22 | NCT04540133 (ClinicalTrials.gov) | December 26, 2020 | 28/8/2020 | Dexamethasone Solution and Dexamethasone in Mucolox™ | Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Inflammatory Ulcerative Diseases | Oral Lichen Planus;Mucous Membrane Pemphigoid;Pemphigus Vulgaris;Chronic Graft-versus-host-disease | Drug: dexamethasone 0.5mg/5ml solution;Drug: dexamethasone 0.5mg/5ml solution in Mucolox™ | University of California, San Francisco | NULL | Completed | 18 Years | N/A | All | 29 | Phase 2 | United States |
| 23 | EUCTR2019-001059-37-BG (EUCTR) | 22/12/2020 | 13/11/2020 | Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid | Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid | Mild to Moderate Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: AKST4290 Product Code: AKST4290 INN or Proposed INN: AKST4290 Other descriptive name: 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE | Alkahest, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 2 | Bulgaria;Germany | ||
| 24 | EUCTR2020-000287-32-BG (EUCTR) | 02/12/2020 | 06/10/2020 | A study to investigate the use of benralizumab in patients with bullous pemphigoid | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD) - FJORD | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Fasenra Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab Other descriptive name: benralizumab | AstraZeneca AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 3 | France;United States;Greece;Spain;Australia;Israel;Bulgaria;Germany;Italy;Japan;China | ||
| 25 | NCT04206553 (ClinicalTrials.gov) | October 28, 2020 | 18/12/2019 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid | Bullous Pemphigoid | Drug: dupilumab;Drug: Matching Placebo;Drug: Oral corticosteroids (OCS) | Regeneron Pharmaceuticals | Sanofi | Recruiting | 18 Years | 90 Years | All | 98 | Phase 2/Phase 3 | United States;Australia;France;Germany;Japan;Poland |
| 26 | EUCTR2019-003520-20-DE (EUCTR) | 15/10/2020 | 26/03/2020 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid - LIBERTY-BP ADEPT | Bullous pemphigoid (BP) MedDRA version: 20.0;Level: PT;Classification code 10034277;Term: Pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Dupixent Product Name: dupilumab INN or Proposed INN: dupilumab Other descriptive name: DUPILUMAB | Regeneron Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 98 | Phase 2;Phase 3 | France;United States;Poland;Australia;Germany;Japan | ||
| 27 | NCT04563923 (ClinicalTrials.gov) | October 10, 2020 | 17/9/2020 | Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody | Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody | Bullous Pemphigoid | Drug: Avdoralimab (IPH5401);Other: Control | Centre Hospitalier Universitaire de Nice | NULL | Recruiting | 18 Years | N/A | All | 40 | Phase 2 | France |
| 28 | NCT04744623 (ClinicalTrials.gov) | September 30, 2020 | 2/2/2021 | Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone | Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone | Benign Mucous Membrane Pemphigoid | Drug: large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP | Tanta University | NULL | Active, not recruiting | 40 Years | 60 Years | All | 10 | Phase 2/Phase 3 | Egypt |
| 29 | NCT04465292 (ClinicalTrials.gov) | September 1, 2020 | 14/5/2020 | The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid | The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid | Pemphigoid, Bullous | Drug: Tildrakizumab Prefilled Syringe | Brigham and Women's Hospital | Joseph Merola | Not yet recruiting | 18 Years | N/A | All | 16 | Early Phase 1 | NULL |
| 30 | EUCTR2020-002912-34-FR (EUCTR) | 11/08/2020 | 22/06/2020 | Treatment of bullous pemphigoid with avdoralimab (IPH5401), an anti-C5aR1 monoclonal antibody | Treatment of bullous pemphigoid with avdoralimab (IPH5401), an anti-C5aR1 monoclonal antibody - PB | Auto Immune bullous Diseases;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: avdoralimab Product Code: IPH5401 INN or Proposed INN: avdoralimab Other descriptive name: NNC0215-0384 | CHU NICE | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Phase 2 | France | ||
| 31 | EUCTR2019-003520-20-FR (EUCTR) | 19/05/2020 | 25/03/2020 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid - LIBERTY-BP ADEPT | Bullous pemphigoid (BP) MedDRA version: 20.0;Level: PT;Classification code 10034277;Term: Pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Dupixent Product Name: dupilumab INN or Proposed INN: dupilumab Other descriptive name: DUPILUMAB | Regeneron Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 80 | Phase 2;Phase 3 | United States;France;Spain;Australia;Germany;Japan | ||
| 32 | NCT04117932 (ClinicalTrials.gov) | March 11, 2020 | 4/10/2019 | Efficacy and Safety of Ustekinumab in Bullous Pemphigoid | Efficacy and Safety of Ustekinumab in Bullous Pemphigoid | Bullous Pemphigoid | Drug: Ustekinumab | CHU de Reims | NULL | Recruiting | 18 Years | 90 Years | All | 18 | Phase 2 | France |
| 33 | NCT04499235 (ClinicalTrials.gov) | January 30, 2020 | 31/7/2020 | A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid | Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid | Pemphigoid, Bullous | Drug: Mometasone furoate;Drug: AKST4290;Drug: Placebo | Alkahest, Inc. | NULL | Completed | 60 Years | 95 Years | All | 30 | Phase 2 | Germany |
| 34 | ChiCTR2000029007 | 2020-01-01 | 2020-01-11 | Clinical observation of subclinical dosage of cyclosporine combined with glucocorticoid in the treatment of moderate and severe bullous pemphigoid | Clinical observation of subclinical dosage of cyclosporine combined with glucocorticoid in the treatment of moderate and severe bullous pemphigoid | Bullous Pemphigoid | experimental group:subclinical dosage of Cyclosporine, Prednisone or Methylprednisolone and Halometasone Cream.;control group:Prednisone or Methylprednisolone, Halometasone Cream; | The First Affiliated Hospital of Kunming Medical University | NULL | Recruiting | Both | experimental group:30;control group:30; | Phase 4 | China | ||
| 35 | ChiCTR2000028707 | 2020-01-01 | 2019-12-31 | Randomized, controlled clinical trial for low-dose interleukin-2 in the treatment of moderate to severe bullous pemphigoid | Randomized, controlled clinical trial for low-dose interleukin-2 in the treatment of moderate to severe bullous pemphigoid | Bullous pemphigoid | Moderate BP group 1:Standard treatment plan;Moderate BP group 2:low dose interleukin-2;Severe BP group 1:Standard treatment plan;Severe BP group 2:low dose interleukin-2; | Dermatology Hospital, Southern Medical University | NULL | Recruiting | 12 | 90 | Both | Moderate BP group 1:34;Moderate BP group 2:34;Severe BP group 1:35;Severe BP group 2:35; | China | |
| 36 | NCT03295383 (ClinicalTrials.gov) | July 11, 2019 | 22/9/2017 | Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid | Randomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid | Severe Forms of Mucous Membrane Pemphigoid | Drug: Rituximab 1g IV;Drug: Cyclophosphamide 50Mg Oral Tablet;Drug: Placebo of Rituximab;Drug: Placebo Oral Tablet | University Hospital, Rouen | NULL | Recruiting | 18 Years | 80 Years | All | 130 | Phase 3 | France |
| 37 | EUCTR2019-001059-37-DE (EUCTR) | 21/06/2019 | 11/06/2019 | Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid | Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid | Mild to Moderate Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: AKST4290 Product Code: AKST4290 INN or Proposed INN: AKST4290 Other descriptive name: 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE | Alkahest, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | Bulgaria;Germany | ||
| 38 | EUCTR2018-002564-10-NL (EUCTR) | 23/04/2019 | 23/04/2019 | PDE4 inhibitor (apremilast) in pemphigoid. | Short-term safety, efficacy and mode of action of apremilast in mild to moderate cutaneous pemphigoid: a phase IIa open label single arm study. - SAMP trial | Pemphigoid;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Otezla Product Name: Apremilast Product Code: CC-10004 | Universitair Medisch Centrum Groningen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 10 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Netherlands | ||
| 39 | NCT03926377 (ClinicalTrials.gov) | April 2019 | 15/4/2019 | Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid | Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid | Osteoporosis;Bullous Pemphigoid | Procedure: bone densitometry;Biological: blood test;Procedure: radiographs of the thoracic and lumbar spine;Procedure: Clobetasol propionate | Centre Hospitalier Universitaire, Amiens | University Hospital, Rouen | Not yet recruiting | 18 Years | N/A | All | 50 | Phase 4 | NULL |
| 40 | NCT04035733 (ClinicalTrials.gov) | September 25, 2018 | 12/4/2019 | rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects | A Phase IIa Open-label Single Arm Study of Safety and Efficacy of rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects | Bullous Pemphigoid (BP) | Drug: rVA576 | AKARI Therapeutics | NULL | Completed | 18 Years | N/A | All | 9 | Phase 2 | Germany;Netherlands |
| 41 | NCT03636763 (ClinicalTrials.gov) | September 2018 | 16/8/2018 | Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? | Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? : Multicenter Retrospective Study in France and Switzerland | Bullous Pemphigoid | Drug: data report | Assistance Publique Hopitaux De Marseille | NULL | Unknown status | N/A | N/A | All | 183 | France | |
| 42 | ChiCTR1800017560 | 2018-08-31 | 2018-08-04 | Association of serum D-dimer and PDF with the BP severity | Association of serum D-dimer and PDF with the BP severity | Bullous pemphigoid | Gold Standard:Clinical outcome;Index test:D-dimer, FDP, anti-BP180 IgG; | the Second Affiliated Hospital, Xi'an Jiaotong University | NULL | Pending | 18 | 90 | Both | Target condition:160;Difficult condition:0 | China | |
| 43 | EUCTR2017-002836-18-DE (EUCTR) | 23/07/2018 | 14/02/2018 | A Clinical study to investigate if rVA576 is safe and has an effect on patients who have mild or moderate Bullous Pemphigoid (a blistering disorder where the skin forms tense blisters) | A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects | Mild to Moderate Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: rVA576 INN or Proposed INN: rVA576 | Akari Therapeutics Plc. | NULL | Not Recruiting | Female: yes Male: yes | 9 | Phase 2 | Netherlands;Germany | ||
| 44 | EUCTR2018-001417-32-FR (EUCTR) | 13/07/2018 | 11/06/2018 | Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3 | Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3. Immunological, clinical and medicoeconomic evaluation | Patients with Bullous pemphigoid included in RITUXIMAB3 study MedDRA version: 20.0;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: MABTHERA INN or Proposed INN: RITUXIMAB Trade Name: Prednisone Product Name: CORTANCYL 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: Prednisone Product Name: CORTANCYL 20 mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE | CHU-Hôpitaux de Rouen | NULL | Not Recruiting | Female: yes Male: yes | 77 | Phase 3 | France | ||
| 45 | EUCTR2017-002836-18-NL (EUCTR) | 07/05/2018 | 24/01/2018 | A Clinical study to investigate if rVA576 is safe and has an effect on patients who have mild or moderate Bullous Pemphigoid (a blistering disorder where the skin forms tense blisters) | A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects | Mild to Moderate Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: rVA576 INN or Proposed INN: rVA576 | Akari Therapeutics Plc. | NULL | Not Recruiting | Female: yes Male: yes | 9 | Phase 2 | Germany;Netherlands | ||
| 46 | JPRN-jRCTs051180069 | 12/04/2018 | 19/02/2019 | Imatinib treatment of autoimmune bullous diseases | Intervention study on autoimmune bullous diseases with imatinib - IABD | Autoimmune bullous disease including pemphigus group and pemphigoid group;D012872 | Imatinib 800 mg a day p.o. for seven days will be started within 14 days of starting steroid therapy (and when the bed is secured). Imatinib 800 mg a day p.o. for seven days will be started afterregistered in the trial (and when the bed is secured) in patients with mild symptoms and will not take systemic steroid therapy. | Kabashima Kenji | Endo Yuichiro | Complete | >= 20age old | < 100age old | Both | 20 | Japan | |
| 47 | NCT03286582 (ClinicalTrials.gov) | September 5, 2017 | 14/9/2017 | A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid | A Randomized, Open-Label, Controlled Trial of Topical AC-203 in Subjects With Bullous Pemphigoid | Bullous Pemphigoid | Drug: AC-203 1% Topical Ointment;Drug: Clobetasol 0.05% Topical Ointment | TWi Biotechnology, Inc. | NULL | Terminated | 20 Years | 90 Years | All | 10 | Phase 2 | Taiwan |
| 48 | NCT03099538 (ClinicalTrials.gov) | August 15, 2017 | 21/3/2017 | Ixekizumab in the Treatment of Bullous Pemphigoid | Ixekizumab in the Treatment of Bullous Pemphigoid | Bullous Pemphigoid;Pemphigoid | Drug: Ixekizumab | Mayo Clinic | Eli Lilly and Company | Completed | 18 Years | N/A | All | 4 | Phase 2 | United States |
| 49 | NCT05284929 (ClinicalTrials.gov) | May 17, 2017 | 10/3/2022 | Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population | Increased Frequencies of Certain HLA Class II Alleles DRB1 and DQB1 in PV Patients Compared to Those in Healthy Donors Have Been Reported in Various Populations and Repeatedly Confirmed. Among the Russian Population, no Studies About the Association of PV and HLA Class II Genes Have Been Conducted. Thus, the Purpose of This Study Was to Investigate HLA Class II Alleles and Haplotypes in Russian Patients With Pemphigus Vulgaris. | Pemphigus;Bullous Pemphigoid;Stevens-Johnson Syndrome;Toxic Epidermal Necrolyses | Genetic: A single blood sample for HLA typing | Sechenov University | Pirogov Russian National Research Medical University | Recruiting | N/A | N/A | All | 120 | Russian Federation | |
| 50 | NCT02993133 (ClinicalTrials.gov) | December 2016 | 12/12/2016 | Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. | Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. | Autoimmune Bullous Dermatose | Drug: Cellcept® in autoimmune bullous dermatoses | University Hospital, Limoges | NULL | Completed | 18 Years | N/A | All | 53 | Phase 3 | France |
| 51 | NCT02226146 (ClinicalTrials.gov) | February 2016 | 27/7/2014 | Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid | An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid | Pemphigoid, Bullous | Biological: Bertilimumab | Immune Pharmaceuticals | NULL | Completed | 60 Years | N/A | All | 11 | Phase 2 | United States;Israel |
| 52 | NCT02502903 (ClinicalTrials.gov) | July 13, 2015 | 7/7/2015 | Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders | Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study. | Bullous Pemphigoid (BP);Cold Agglutinin Disease (CAD);Warm Autoimmune Hemolytic Anemia (WAIHA);End-stage Renal Disease (ESRD) | Drug: BIV009;Other: Placebo | Bioverativ, a Sanofi company | Celerion Clinical Research GmbH;Assign Data Management and Biostatistics GmbH;ABF Pharmaceutical Services GmbH;Quest Diagnostics-Nichols Insitute;Covance Laboratories - Chantilly;PPD Laboratories - Virginia;Softworld Inc. - Cambridge, MA | Completed | 18 Years | N/A | All | 122 | Phase 1 | Austria |
| 53 | NCT02360202 (ClinicalTrials.gov) | April 2015 | 7/1/2015 | Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid | Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid | Bullous Pemphigoid | Procedure: Impedance analysis;Drug: Clobetasol Propionate cream treatment | University Hospital, Rouen | Société de Dermatologie Française | Recruiting | 18 Years | N/A | All | 35 | Phase 4 | France |
| 54 | JPRN-UMIN000015451 | 2014/11/13 | 25/10/2014 | Exploratory research on effectiveness and safety of Rituximab treatment including maintenance administration for steroid intractable autoimmune bullous diseases of the skin.Rtx-BD Trial (Rituximab of Intractable Autoimmune Bullous Disease Trial) 2 | Exploratory research on effectiveness and safety of Rituximab treatment including maintenance administration for steroid intractable autoimmune bullous diseases of the skin.Rtx-BD Trial (Rituximab of Intractable Autoimmune Bullous Disease Trial) 2 - Rtx-BD Trial 2 | Pemphigus, Pemphigoid | Rituximab 375mg/sqm, q1w, 4 doses. Maintenance administration of rituximab is possible if PDA or BPDAI is between 1 and 10 on week 24 to 48 | Department of Dermatology,Keio University School of Medicine | Hokkaido University, Kurume University, Okayama University, Kawasaki Medical School | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 20 | Phase 1,2 | Japan |
| 55 | NCT02126020 (ClinicalTrials.gov) | November 2014 | 27/4/2014 | Topical Infliximab in Autoimmune Eyes With Keratoprosthesis | Topical Infliximab in Autoimmune Eyes With Keratoprosthesis | Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane Pemphigoid | Drug: topical infliximab | James Chodosh, MD, MPH | Massachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM) | Withdrawn | 18 Years | 80 Years | All | 0 | Phase 1/Phase 2 | United States;Canada |
| 56 | JPRN-jRCTs031180220 | 01/05/2014 | 15/03/2019 | Rituximab treatment of blistering disease | Treatment of refractory autoimmuno blistering disease with rituximab | Pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid | Infusion of rituximab (1000mg) intravenously. Approximately two weeks after the first dose, a second dose of rituximab is administered in a similar manner. | Kanaoka Miwa | Michiko Aihara | Complete | >= 20age old | < 80age old | Both | 10 | N/A | Japan |
| 57 | NCT02149732 (ClinicalTrials.gov) | May 2014 | 14/5/2014 | Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation | An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients | Limbal Stem Cell Deficiency;Stevens-johnson Syndrome;Ocular Cicatricial Pemphigoid;Chemical Burn | Biological: cultivated oral mucosal epithelial sheet transplantation | Seoul National University Hospital | Ministry of Health & Welfare, Korea | Available | 16 Years | N/A | Both | Phase 1/Phase 2 | Korea, Republic of | |
| 58 | EUCTR2012-003370-10-FR (EUCTR) | 24/05/2013 | 28/09/2015 | Safety, efficacy and PK/PD of QGE031 vs. placebo in patients with active bullous phemphigoid despite oral steroid treatment. | A randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with bullous pemphigoid with disease refractory to oral steroid treatment | refractory bullous pemphigoid MedDRA version: 18.0;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: QGE031 | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 42 | Phase 2 | United States;France;Taiwan;Austria;Germany | ||
| 59 | NCT02837965 (ClinicalTrials.gov) | April 2013 | 24/6/2016 | Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid | Multicenter Prospective Observational Study Assessing Outcomes, Adverse Events, Treatment Patterns and Related Costs in Patients Diagnosed With Bullous Pemphigoid | Bullous Pemphigoid | Drug: treatment with topical superpotent corticosteroid therapy;Drug: treatment with systemic therapy (methotrexate);Drug: treatment systemic therapy (prednisone);Drug: treatment with systemic therapy (prednisone);Drug: treatment with systemic therapy (doxycycline) | CHU de Reims | NULL | Recruiting | 18 Years | N/A | Both | 150 | N/A | France |
| 60 | EUCTR2011-004361-32-DE (EUCTR) | 26/02/2013 | 22/05/2012 | Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid | Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoidA prospective multi-centre randomised double-blind placebo-controlled pilot study - SICOPEM | Bullous pemphigoid (BP) is the most frequent blistering autoimmune disease of the skin. The disease itself is characterized by the development of bullous lesions, frequently following a prodromal phase with severe itching. Between 10 to 30 percent of patients exhibit mucosal membrane involvement in addition to the skin lesions.;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Simvastatin-ratiopharm® Product Name: Simvastatin-ratiopharm Other descriptive name: SIMVASTATIN | Philipps-Universität Marburg | NULL | Not Recruiting | Female: yes Male: yes | Germany | ||||
| 61 | NCT01705795 (ClinicalTrials.gov) | February 13, 2013 | 5/10/2012 | Anti-IL-5 Therapy in Bullous Pemphigoid (BP) | Anti-IL-5 Therapy in Bullous Pemphigoid. Randomized, Placebo-controlled, Double-blind Study Evaluating the Effect of Anti-IL-5 Therapy in Patients With Bullous Pemphigoid. | Pemphigoid, Bullous | Drug: Mepolizumab (a-IL-5 antibody);Drug: Placebo | University Hospital Inselspital, Berne | NULL | Completed | 18 Years | N/A | All | 32 | Phase 2 | Switzerland |
| 62 | EUCTR2012-003370-10-DE (EUCTR) | 23/01/2013 | 23/10/2012 | Safety, efficacy and PK/PD of QGE031 vs. placebo in patients with active bullous phemphigoid despite oral steroid treatment. | A randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with bullous pemphigoid with disease refractory to oral steroid treatment | Refractory Bullous Pemphigoid MedDRA version: 16.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: QGE031 INN or Proposed INN: QGE031 | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 42 | United States;Taiwan;Austria;Germany | |||
| 63 | NCT01688882 (ClinicalTrials.gov) | January 2013 | 17/9/2012 | Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment | A Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Bullous Pemphigoid With Disease Refractory to Oral Steroid Treatment | Bullous Pemphigoid | Drug: QGE031;Drug: Placebo | Novartis Pharmaceuticals | NULL | Terminated | 20 Years | 80 Years | All | 20 | Phase 2 | United States;Austria;France;Germany;Japan;Taiwan |
| 64 | EUCTR2012-003370-10-AT (EUCTR) | 13/11/2012 | 03/10/2012 | Safety, efficacy and PK/PD of QGE031 vs. placebo in patients with active bullous phemphigoid despite oral steroid treatment. | A randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with bullous pemphigoid with disease refractory to oral steroid treatment | Refractory Bullous Pemphigoid MedDRA version: 15.0;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: QGE031 | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 42 | United States;Taiwan;Austria;Germany | |||
| 65 | NCT01582880 (ClinicalTrials.gov) | March 2012 | 10/4/2012 | Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis | The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis | Chemical Injuries;Unspecified Complication of Corneal Transplant;Autoimmune Diseases;Ocular Cicatricial Pemphigoid;Stevens Johnson Syndrome;Lupus Erythematosus, Systemic;Rheumatoid Arthritis;Other Autoimmune Diseases | Drug: Riboflavin | Joseph B. Ciolino, MD | NULL | Completed | 18 Years | N/A | All | 1 | Phase 1/Phase 2 | United States |
| 66 | NCT01571895 (ClinicalTrials.gov) | February 20, 2012 | 4/4/2012 | Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid | A Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid. | Bullous Pemphigoid | Drug: DF2156A | Dompé Farmaceutici S.p.A | NULL | Terminated | 18 Years | N/A | All | 4 | Phase 2 | Germany;Italy |
| 67 | ChiCTR-TRC-12003538 | 2011-08-01 | 2012-12-27 | Use of inravenous Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trial | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | Bullous pemphigoid | Glucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.; | Institute of dermatology, Chinese Academy of Medical Sciences | NULL | Recruiting | 18 | 0 | Both | Glucocorticoids group:90;Glucocorticoid plus MTX group:90; | China | |
| 68 | ChiCTR-TRC-12003593 | 2011-08-01 | 2012-12-30 | Use of Oral Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trial | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | bullous pemphigoid | Glucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses.;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.; | Institute of dermatology; Chinese Academy of Medical Sciences | NULL | Completed | 18 | Both | Glucocorticoids group:90;Glucocorticoid plus MTX group:90; | China | ||
| 69 | ChiCTR-TRC-12003592 | 2011-08-01 | 2012-12-30 | Use of Tripterygium glycosides and Nicotinamide plus Minocycline for the Treatment of bullous pemphigoid: A multicenter,randomized and controlled clinincal trial | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | Bullous pemphigoid | Tripterygium glycosides group:Take tripterygium glycosides orally at 20 mg, 3 times a day;Nicotinamide plus Minocycline group:Take nicotinamide at 500 mg, 3 times a day and minocycline 100 mg, twice a day.; | Institute of dermatology, Chinese Academy of Medical Sciences | NULL | Completed | 18 | Both | Tripterygium glycosides group:100;Nicotinamide plus Minocycline group:100; | China | ||
| 70 | NCT01408550 (ClinicalTrials.gov) | August 2011 | 27/7/2011 | Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids | NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase III) | Bullous Pemphigoid | Drug: NPB-01;Drug: Placebo | Nihon Pharmaceutical Co., Ltd | NULL | Completed | 20 Years | N/A | Both | 56 | Phase 3 | Japan |
| 71 | EUCTR2011-000756-42-IT (EUCTR) | 30/06/2011 | 20/03/2012 | pilot phase 2 clinical trial performed in some hospitals to evaluate the efficacy and the adverse events in a group of patients with active bullous pemphigoid that will receive DF2156A at the dose of 150 mg, oral route, twice a day. | A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. - DF2156A in bullous pemphigoid | active bullous pemphigoid MedDRA version: 14.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: NA Product Code: DF2156A INN or Proposed INN: ladarixin | DOMPE' s.p.a. | NULL | Not Recruiting | Female: yes Male: yes | 12 | Phase 2 | Germany;Italy | ||
| 72 | JPRN-UMIN000004428 | 2010/11/01 | 01/11/2010 | Exploratory research on effectiveness and safety of Rituximab treatment for steroid intractable pemphygus, bullous pemphigoid and epidermolysis bullosa acquisita. | Exploratory research on effectiveness and safety of Rituximab treatment for steroid intractable pemphygus, bullous pemphigoid and epidermolysis bullosa acquisita. - Rtx-BD Trial | pemphigus, bullous pemphigoid, epidermolysis bullosa acquisita | Rituximab | Research group of rare intractable dermatologial disorder | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 20 | Phase 2 | Japan |
| 73 | EUCTR2007-006658-24-DE (EUCTR) | 16/12/2009 | 08/09/2009 | A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study | A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study | BP is a serious condition with a significant associated morbidity and mortality rate. Widespread tense and haemorrhagic blisters, skin erosions and severe itching cause patients a great deal of distress and pain. It occurs mainly in the elderly. The mortality rate in treated patients is estimated to range from 20% - 40% at one year. MedDRA version: 9.1;Level: LLT;Classification code 10006568;Term: Bullous pemphigoid NOS MedDRA version: 9.1;Classification code 10006567;Term: Bullous pemphigoid | Product Name: prednisolone INN or Proposed INN: prednisolone Product Name: doxycycline INN or Proposed INN: doxycycline | Universitätsklinikum Schleswig-Holstein | NULL | Not Recruiting | Female: yes Male: yes | 256 | Phase 4 | Germany;United Kingdom | ||
| 74 | ChiCTR-IOR-15007146 | 2009-10-01 | 2015-09-17 | Combined treatment with low dose systemic steroids andtopical steroids in bullous pemphigoid andfactors of treatment-refractory bullous pemphigoid | Efficacy of low dose systemic steroids combined with topical steroids in the treatment of bullous pemphigoid andrisk factors for treatment-refractory patients:A Randomized Controlled Trial | bullous pemphigoid | Control Group (C):apply 0.05% halometasone cream daily;Treatment Group (T):apply 0.05% halometasone cream daily+low-dose systemic steroids; | Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine | NULL | Completed | Both | Control Group (C):40;Treatment Group (T):40; | China | |||
| 75 | EUCTR2007-006658-24-GB (EUCTR) | 05/03/2009 | 22/10/2008 | A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study | A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study | BP is a serious condition with a significant associated morbidity and mortality rate. Widespread tense and haemorrhagic blisters, skin erosions and severe itching cause patients a great deal of distress and pain. It occurs mainly in the elderly. The mortality rate in treated patients is estimated to range from 20% - 40% at one year. MedDRA version: 14.0;Level: LLT;Classification code 10006568;Term: Bullous pemphigoid NOS;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 14.0;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders | Product Name: prednisolone INN or Proposed INN: prednisolone Product Name: doxycycline INN or Proposed INN: doxycycline Product Name: prednisolone INN or Proposed INN: prednisolone Product Name: prednisolone INN or Proposed INN: prednisolone Product Name: doxycycline INN or Proposed INN: doxycycline | University of Nottingham | NULL | Not Recruiting | Female: yes Male: yes | 256 | Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4): yes | Germany;United Kingdom | ||
| 76 | EUCTR2008-005266-31-FR (EUCTR) | 06/02/2009 | 13/03/2009 | COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III | COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III | Pemphogoide bulleuse MedDRA version: 9.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid | Trade Name: mabthéra Product Name: mathéra Trade Name: Prednisone Product Name: CORTANCYL 20 mg | CHU-Hôpitaux de Rouen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France | ||||
| 77 | NCT00525616 (ClinicalTrials.gov) | December 2008 | 20/7/2007 | Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid | Assessment of Rituximab Efficiency and Tolerance in Treatment of Bullous Pemphigoid. | Bullous Pemphigoid | Drug: Mabthera | University Hospital, Rouen | NULL | Completed | 18 Years | 80 Years | Both | 18 | Phase 3 | France |
| 78 | NCT00809822 (ClinicalTrials.gov) | November 2008 | 11/12/2008 | Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. | NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase?). | Bullous Pemphigoid | Drug: NPB-01;Drug: Placebo | Nihon Pharmaceutical Co., Ltd | NULL | Completed | 20 Years | N/A | Both | 20 | Phase 2 | Japan |
| 79 | EUCTR2008-000480-41-IT (EUCTR) | 27/05/2008 | 10/06/2008 | Multicenter, randomised, double masked, controlled clinical trial on the safety and efficacy of Cyclosporine A eyedrop treatment on patients with ocular cicatricial pemphigoid. - ND | Multicenter, randomised, double masked, controlled clinical trial on the safety and efficacy of Cyclosporine A eyedrop treatment on patients with ocular cicatricial pemphigoid. - ND | Ocular cicatricial pemphigoid (OCP) MedDRA version: 9.1;Level: LLT;Classification code 10010746;Term: Conjunctivitis chronic | Trade Name: RESTASIS INN or Proposed INN: Cyclosporine | UNIVERSITA' CAMPUS BIOMEDICO | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
| 80 | NCT02313870 (ClinicalTrials.gov) | January 22, 2008 | 8/12/2014 | Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid | Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid | Bullous Pemphigoid | Drug: clobetasol propionate + Methotrexate;Drug: clobetasol propionate alone | University Hospital, Montpellier | NULL | Completed | 18 Years | N/A | All | 322 | Phase 3 | France |
| 81 | EUCTR2007-003545-32-FR (EUCTR) | 14/09/2007 | 23/07/2007 | Etude prospective ouverte de l'efficacité du leflunomide dans le traitement de la pemphigoïde bulleuse en association aux dermocorticoïdes. - ARABUL | Etude prospective ouverte de l'efficacité du leflunomide dans le traitement de la pemphigoïde bulleuse en association aux dermocorticoïdes. - ARABUL | Pemphigoïde bulleuse MedDRA version: 9.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid | Trade Name: ARAVA Trade Name: DERMOVAL | CHU de Limoges | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France | ||||
| 82 | NCT00802243 (ClinicalTrials.gov) | September 2007 | 3/12/2008 | Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid | Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid. An Open Prospective Study | Bullous Pemphigoid | Drug: leflunomide | University Hospital, Limoges | NULL | Recruiting | 65 Years | N/A | Both | 54 | Phase 2 | France |
| 83 | NCT00472030 (ClinicalTrials.gov) | August 2007 | 8/5/2007 | Efficacy and Safety of Omalizumab in Bullous Pemphigoid | An Open Label Case Series on the Effects of Xolair (Omalizumab) in Bullous Pemphigoid | Bullous Pemphigoid | Drug: Omalizumab;Drug: prednisone | University of Iowa | Genentech, Inc. | Completed | 18 Years | N/A | All | 2 | Phase 4 | United States |
| 84 | NCT00584935 (ClinicalTrials.gov) | January 2006 | 26/12/2007 | Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid | Phase I/II Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid | Ocular Cicatricial Pemphigoid | Drug: Rituximab | University of Alabama at Birmingham | Genentech, Inc.;Biogen | Completed | 19 Years | N/A | All | 3 | Phase 1/Phase 2 | United States |
| 85 | EUCTR2005-001827-12-DE (EUCTR) | 29/12/2005 | 12/07/2005 | Myfortic ® zur Therapie des Bullösen Pemphigoids. Eine offene monozentrische proof-of-concept Studie | Myfortic ® zur Therapie des Bullösen Pemphigoids. Eine offene monozentrische proof-of-concept Studie | Bullous Pemphigoid | Trade Name: Myfortic 180 mg Product Name: Myfortic 180 mg Filmtabletten | Georg-August-Universität Göttingen, Bereich Humanmedizin | NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 2 | Germany | ||
| 86 | EUCTR2005-002391-14-GB (EUCTR) | 29/09/2005 | 23/08/2005 | Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study - IVMP for ocular pemphigoid | Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study - IVMP for ocular pemphigoid | ocular mucous membrane pemphigoid | Trade Name: Solu-Medrone | Moorfields Eye Hospital NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | 20 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom | ||
| 87 | NCT00286325 (ClinicalTrials.gov) | March 2005 | 1/2/2006 | Rituximab in the Treatment of Patients With Bullous Pemphigoid | Rituximab in the Treatment of Patients With Bullous Pemphigoid | Bullous Pemphigoid | Drug: Rituximab | Duke University | Genentech, Inc. | Completed | 18 Years | N/A | All | 8 | Phase 1/Phase 2 | United States |
| 88 | NCT00213421 (ClinicalTrials.gov) | August 2001 | 13/9/2005 | Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus | Bullous Pemphigoid | Drug: Dermoval | University Hospital, Rouen | NULL | Completed | 18 Years | N/A | Both | 330 | France | ||
| 89 | NCT00431119 (ClinicalTrials.gov) | October 1997 | 2/2/2007 | Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid | A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid | Bullous Pemphigoid | Drug: Azathioprine or Mycophenolate mofetil | University Hospital Muenster | Hoffmann-La Roche | Completed | 18 Years | 90 Years | Both | 70 | Phase 2 | Germany |
| 90 | EUCTR2011-000756-42-DE (EUCTR) | 08/06/2011 | Pilot phase 2 clinical trial performed in some hospitals to evaluate the efficacy and the adverse events in a group of patients with active bullous pemphigoid that will receive DF2156A at the dose of 150 mg, oral route, twice a day. | A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. - DF2156A in patients with active bullous pemphigoid | active bullous pemphigoid MedDRA version: 14.0;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: not applicable Product Code: DF2156A INN or Proposed INN: ladarixin | Dompé s.p.a. | NULL | Not Recruiting | Female: yes Male: yes | 12 | Phase 2 | Germany;Italy |